CTRI/2019/09/021373
Completed
Phase 3
A prospective, multicentric, randomized, double-blind, parallel, phase III clinical study to assess efficacy of PMZ-1620 along with standard treatment in patients of acute ischemic stroke.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
- Sponsor
- Pharmazz India Private Limited
- Enrollment
- 158
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adult males or females Aged 18 years through 78 years (have not had their 79th birthday).
- •2\. Patient or Legally Acceptable Representative (LAR) willing to give informed Consent before study procedure.
- •3\. Stroke is ischemic in origin and radiologically confirmed Computed Tomography (CT) scan or diagnostic magnetic resonance imaging (MRI) prior to enrolment. No hemorrhage as proved by cerebral CT/MRI scan.
- •4\. Cerebral ischemic stroke patients presenting upto 24 hours after onset of symptoms with mRS score of 3\-4 (pre\-stroke mRS score of 0 or 1\) and NIHSS score \>5 (NIHSS Level of Consciousness (1A) score must be \< 2\). This also includes patients who had ischemic stroke in the past and are completely recovered from earlier episode before having new or fresh stroke.
- •5\. Patient is \< 24 hours from time of stroke onset when the first dose of PMZ\-1620 therapy is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when patient was last seen or was self\- reported to be normal
- •6\. Reasonable expectation of availability to receive the full PMZ\-1620 course of therapy, and to be available for subsequent follow\-up visits
Exclusion Criteria
- •1\. Patients receiving endovascular therapy or is a candidate for any surgical intervention for treatment of stroke which may include but not limited to endovascular techniques
- •2\. Patients classified as comatose, defined as a patient who required repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (NIHSS Level of Consciousness (1A) score more than or equal to 2\)
- •3\. Evidence of intracranial hemorrhage (intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, acute or chronic subdural hematoma on the baseline CT or MRI scan.
- •4\. Known pregnancy
- •5\. Confounding pre\-existing neurological or psychiatric disease
- •6\. Concurrent participation in any other therapeutic clinical trial
- •7\. Evidence of any other major life\-threatening or serious medical condition that would prevent completion of the study protocol, impair the assessment of outcome, or in which PMZ\-1620 therapy would be contraindicated or might cause harm to the patient
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
sovateltide Injection for the treatment of acute cerebral ischemic strokeHealth Condition 1: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteriesCTRI/2023/12/060404Pharmazz India Private Limited
Recruiting
Phase 3
A Clinical trial to evaluate the efficacy, safety and tolerability of FDC of Dapagliflozin 10mg and Telmisartan 80mg in patients with chronic kidney diseaseHealth Condition 1: N189- Chronic kidney disease, unspecifiedCTRI/2024/04/065084ERIS LIFESCIENCES LIMITED
Completed
Phase 3
A clinical trial to study the safety and efficacy of 2mg and 4mg of ZYH1 compared to placebo in hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VI)].Health Condition 1: E785- Hyperlipidemia, unspecifiedHealth Condition 2: null- In hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.CTRI/2009/091/000533Cadila Healthcare Limited300
Completed
Not Applicable
Evaluation of iloprost in the postoperative period after liver transplantatioiver transplantationInjury, Occupational Diseases, PoisoningLiver transplant failure and rejectionISRCTN12622749Friedrich-Schiller-University Jena (Germany)356
Active, not recruiting
Phase 1
A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantatioEUCTR2010-022660-12-DEFriedrich Schiller University430